ライフサイエンスコーパス: phosphoramidate

1 oavailability of the corresponding monoester phosphoramidate.

2 with ammonium hydroxide to form the desired phosphoramidate.

3 ation steps to obtain pure ammonium hydrogen phosphoramidate.

4 l phosphate, 2-methoxybenzoyl phosphate, and phosphoramidate.

5 r to that of the corresponding beta-anomeric phosphoramidate.

6 nophosphoimidazole and pH 7.8 (midpoint) for phosphoramidate.

7 described phosphodonors acetyl phosphate and phosphoramidate.

8 Both CPSs were shown to carry O-methyl-phosphoramidate.

9 hat can be directly transformed into allylic phosphoramidates.

10 de linkages as N, N -diethylethylene-diamine phosphoramidates.

11 strands, as well as with 2'-deoxy N3'-->P5' phosphoramidates.

12 n and phosphorus, leading to cyclic P-chiral phosphoramidates.

13 lly similar 3'-azido-3'-deoxythymidine (AZT) phosphoramidates 1-6 and 3'-fluoro-3'-deoxythymidine (FL

14 Phosphoramidate (1) and its fluorobenzamido conjugate (2

15 )hydroxyphosphorylamino) -pentanedioic acid (Phosphoramidate (1)), yielding S-2-((2-(S-4-(4-(18)F-flu

16 estinal microsomes and liver microsomes make phosphoramidate 16 a prospective candidate for further s

17 Phosphoramidate 16 in its 5'-triphosphate form specifica

18 Studies on the intracellular half-life of phosphoramidate 16-TP in live cells demonstrated favorab

19 Phosphoramidates (18-21) achieved a significant improvem

20 The results obtained with hypoxallene phosphoramidates 2b and 4b indicate that the aminosuccin

21 (18)F-labeled phosphoramidate (3) is a representative of a new class o

22 In general, hHint3s hydrolyze phosphoramidate 370- to 2000-fold less efficiently than

23 xy-5'-uridyl N-(1-carbomethoxy-2-phenylethyl)phosphoramidate (5a), 5-fluoro-2'-deoxy-5'- uridyl N-(1-

24 -5'- uridyl N-(1-carbomethoxy-2-indolylethyl)phosphoramidate (5b), 1-beta-arabinofuranosylcytosine 5'

25 es 1-6 and 3'-fluoro-3'-deoxythymidine (FLT) phosphoramidates 7-10 are reported.

26 of a duplex formed by a 13mer ribo-N3'-->P5' phosphoramidate (84 degrees C) was higher than that obse

27 the two AZT aromatic amino acid methyl ester phosphoramidates 8a and 9a were found to be more cytotox

28 Ara-C phosphoramidates 8a,b were found to be inactive at a con

29 cytosine 5'-N-(1-carbomethoxy-2-phenylethyl) phosphoramidate (8a), and 1-beta-arabinofuranosylcytosin

30 cytosine 5'-N-(1-carbomethoxy-2-indolylethyl)phosphoramidate (8b), were synthesized and tested for th

31 tions as high as 100 microM, whereas the FLT phosphoramidates 9 and 10 had CC50 values of 95.6 and 35

32 rate constants (kphos/KS) for reaction with phosphoramidate, acetyl phosphate, or monophosphoimidazo

33 The RNA phosphoramidates also showed similar rates of hydrolysis

34 We find that TFOs containing N3'-->P5' phosphoramidate (amidate), 5-(1-propynyl)-2'-deoxyuridin

35 ate, ADP.Mg(2+).phosphopantothenate, and AMP phosphoramidate (AMPPN).Mg(2+), revealed a large conform

36 Primer extensions with phosphoramidate analogs of dNTPs allowed for unambiguous

37 Piperidyl phosphoramidate analogues are also converted to nucleoti

38 Synthetic phosphoramidate analogues of nucleosides have been used

39 On the basis of these data, a series of phosphoramidate analogues with structural variation in t

40 e duplex conformation of the oligonucleotide phosphoramidate and confirm that all furanose rings of 3

41 phorus bond in both monophosphoimidazole and phosphoramidate and implied that CheY was not capable of

42 re unaffected by pH over this range, whereas phosphoramidate and monophosphoimidazole showed a steep

43 ith acetyl phosphate and faster (4-14x) with phosphoramidate and monophosphoimidazole.

44 orylation rate, especially for reaction with phosphoramidate and monophosphoimidazole.

45 Both phosphoramidate and phosphorothioate oligonucleotides we

46 droxamate by synthesizing a small library of phosphoramidates and evaluating their biological activit

47 Hint1 catalyzes the hydrolysis of purine phosphoramidates and lysyl-adenylate generated by lysyl-

48 several different deoxyguanosine nucleotide phosphoramidates and phosphomonoesters were synthesized

49 ese compounds relative to the beta-N3'-->P5' phosphoramidates and to the alpha-phosphodiester counter

50 honate, pinacolyl methylphosphonate, diethyl phosphoramidate, and 2-(butylamino)ethanethiol) and one

51 sphonate, diethyl ethyl phosphonate, diethyl phosphoramidate, and diethyl phthalate using laser fluen

52 s suggest that the oligonucleotide N3'-->P5' phosphoramidates, and particularly thio-phosphoramidates

53 Generation of the phosphoramidate anion leads to cyclization and subsequen

54 release of nucleotide via cyclization of the phosphoramidate anion to the aziridinium ion intermediat

55 ndergoes intracellular activation liberating phosphoramidate anion, which undergoes spontaneous cycli

56 racellularly with concomitant expulsion of a phosphoramidate anion.

57 )P NMR kinetics demonstrated that all of the phosphoramidate anions cyclized to the aziridinium ion a

58 led to rapid expulsion of the corresponding phosphoramidate anions in both series of compounds.

59 essed the inhibitory potential of morpholino phosphoramidate antisense oligonucleotides (morpholinos)

60 uniformly modified oligonucleotide N3'-->P5' phosphoramidates are apparently more potent antisense ag

61 Phosphoramidates are modified deoxyoligonucleotides that

62 In addition to their inherent value, the phosphoramidates are precursors to enantioenriched epoxy

63 Oligodeoxynucleotide N3'-->P5' phosphoramidates are promising candidates for antisense

64 was shown in this study, the oligonucleotide phosphoramidates are resistant to digestion with snake v

65 RNA mimetics, oligoribonucleotide N3'-->P5' phosphoramidates, are described.

66 -anomeric oligodeoxyribonucleotide N3'-->P5' phosphoramidates, are described.

67 The present study uses N3'-phosphoramidate as a control to understand the changes i

68 The motivation of this work is to explore phosphoramidates as a new class of potent PSMA inhibitor

69 enzymes preferred guanosine versus adenosine phosphoramidates as substrates.

70 evaluated several oligonucleotide N3'-->P5' phosphoramidates as telomerase inhibitors.

71 C-myb antisense phosphoramidates at 5 microM caused sequence and dose-de

72 iously uncharacterized properties of the N3'-phosphoramidate backbone are also observed and explained

73 DNA-RNA molecules, both with and without the phosphoramidate backbone modifications, we show that the

74 hosphates has been developed that utilizes a phosphoramidate-based prodrug approach.

75 intracellular delivery of nucleotides using phosphoramidate-based prodrugs is described.

76 A series of phosphoramidate-based prostate specific membrane antigen

77 A series of thymidine and tetrahydrofurfuryl phosphoramidates bearing haloethyl or piperidyl substitu

78 onate (AmNS) to the terminal phosphate via a phosphoramidate bond.

79 C), extending the donor by one residue via a phosphoramidate bond.

80 rtate alpha-carboxyl group linked to AMP via phosphoramidate bond.

81 acid lability of the P( horizontal lineO)-N phosphoramidate bond.

82 e but resistant to alkali, consistent with a phosphoramidate bond.

83 ntaining acid-labile internucleotide P3'-N5' phosphoramidate bonds, either in a surface-bound form or

84 e phosphodonors such as acetyl phosphate and phosphoramidate, but it is phosphorylated by the cognate

85 int3-2 prefer AIPA over tryptamine adenosine phosphoramidate by factors of 33- and 16-fold, respectiv

86 Rapid hydrolysis of Spo0F-P generated with phosphoramidate by proteins downstream in the phosphorel

87 ver, gel shift assays demonstrate that these phosphoramidates can specifically bind to peptides deriv

88 C) than that for the isosequential 2'-deoxy phosphoramidate complex.

89 P NMR studies carried out on model haloethyl phosphoramidates confirm the release of nucleotide via c

90 Using this novel assay, phosphoramidate containing compounds were found to speci

91 modified oligodeoxyribonucleotide N3'-->P5' phosphoramidates containing 2'-fluoro-2'-deoxy-pyrimidin

92 ormly modified oligoribonucleotide N3'-->P5' phosphoramidates containing all four natural bases (urac

93 ec chimera does not exhibit a preference for phosphoramidates containing d- or l- tryptophan, while t

94 sults suggest that the lipid-conjugated thio-phosphoramidates could be important for improved pharmac

95 data indicate that oligonucleotide N3'-->P5' phosphoramidates could be used as specific and efficient

96 .0 degrees C), or for the 2'-deoxy-N3'-->P5' phosphoramidate counterpart (71.7 degrees C).

97 degrees C relative to the 2'-deoxy N3'-->P5' phosphoramidate counterpart.

98 han that for the corresponding beta-anomeric phosphoramidate counterpart.

99 tudies of model dimers d(TpT) and N3'--> P5' phosphoramidate d(TnpT) show that the sugar ring conform

100 Thus the N3'-->P5' phosphoramidate decamer containing only alpha-thymidine

101 f NarLN by a small-molecule phosphate donor, phosphoramidate, decreases this interaction about 25-fol

102 er, d(AnTnGnAnCn)rU, contains an N3' --> P5' phosphoramidate deoxysugar-phosphate backbone (n) that i

103 TS are preferentially sensitive to NB1011, a phosphoramidate derivative of (E)-5-(2-bromovinyl)-2'-de

104 X4430, an imino-C-nucleoside, and GS-6620, a phosphoramidate derivative of 1'-cyano-2'-C-methyl-4-aza

105 In addition, after oral dosing of several phosphoramidate derivatives of compound 21 to rats, subs

106 Moreover, tissue distribution of the phosphoramidate derivatives was undistinguishable from t

107 However, s-BuLi converted the dimethyl N-Boc-phosphoramidate derived from 1-phenylethylamine to the N

108 LiTMP metalated dimethyl N-Boc-phosphoramidates derived from 1-phenylethylamine and 1,2

109 actions of a variety of amino acids with the phosphoramidates derived from oligonucleotide 5'-phospha

110 ved for these prodrugs, but the intermediate phosphoramidate dianion underwent spontaneous hydrolysis

111 , we evaluate the impact of HCV-NS5B prodrug phosphoramidate diastereochemistry (D-/L-alanine, R-/S-p

112 phoramidate monoester and positively charged phosphoramidate diester groups were synthesized.

113 resulted in formation of an internucleoside phosphoramidate diester.

114 The amino acid phosphoramidate diesters of FUdR (2) and Ara-C (6), 5-fl

115 y, it is proposed that the metabolism of the phosphoramidate diesters of FUdR in proliferating tissue

116 amidate monoesters are distinct from that of phosphoramidate diesters.

117 ethod.1H NMR analysis of the alpha-N3'-->P5' phosphoramidate dimer structures indicates significant d

118 Poly(phosphoramidate-dipropylamine) (PPA) and Lipid-Protamine

119 The initial rate of Spo0F-P formation from phosphoramidate displays Michaelis-Menten kinetics, prov

120 we describe the synthesis of N3'-P5'-linked phosphoramidate DNA (3'-NP-DNA) by the template-directed

121 N3'-P5'-linked phosphoramidate DNA (3'-NP-DNA) is similar to RNA in its

122 structural and biochemical properties of N3'-phosphoramidate DNA analogs have been re-examined using

123 The N3'-phosphoramidate DNA backbone differs from the phosphodie

124 Solvation of N3'-phosphoramidate DNA is shown to be similar to RNA, consi

125 template copying and suggest that N2'-->P5'-phosphoramidate DNA may have the potential to function a

126 titution was performed via comparison of N3'-phosphoramidate DNA starting from both A- and B-form str

127 e-directed solid-phase syntheses for RNA and phosphoramidate DNA.

128 We now report that oligonucleotide N3'-->P5' phosphoramidates DNA analogs of HIV-1 RRE IIB and TAR RN

129 The tight binding of the phosphoramidate duplex under metal-free conditions and i

130 reased chemical shift dispersion in the free phosphoramidate duplex, the spectrum of the enzyme-bound

131 The AZT phosphoramidates exhibited no cytotoxicity toward CEM ce

132 A series of novel haloethyl and piperidyl phosphoramidate FdUMP prodrug analogues has been synthes

133 was 5-14 degrees C relative to the 2'-deoxy phosphoramidates for decanucleotides.

134 des and derivatives thereof, including their phosphoramidates, for their therapeutic potential in the

135 repared oligo-2'-fluoro-nucleotide N3'-->P5' phosphoramidates form extremely stable duplexes with com

136 experiments demonstrated that ribo-N3'-->P5' phosphoramidates form stable duplexes with a complementa

137 thermore, the oligopyrimidine ribo N3'-->P5' phosphoramidate formed an extremely stable triplex with

138 The covalent linkage is a phosphoramidate formed between the UMP moiety and the Hi

139 n contrast, the alpha-decaadenylic N3'-->P5' phosphoramidate formed duplexes with both RNA and DNA co

140 0.5 microM of FuGENE6 formulated 13-mer thio-phosphoramidates, fully complementary to hTR, resulted i

141 A task specific ionic liquid (TSIL) bearing phosphoramidate group, viz., N-propyl(diphenylphosphoram

142 do when the 3'-phosphoester is replaced by a phosphoramidate group.

143 ent method for the synthesis of radiolabeled phosphoramidate has not been developed, and this has lim

144 A series of novel nitroheterocyclic phosphoramidates has been evaluated for antitumor activi

145 A series of novel nitroheterocyclic phosphoramidates has been prepared, and the cytotoxicity

146 e boranophosphates and nucleoside amino acid phosphoramidates have been shown to be potent antiviral

147 able to cleave the native strand in a native:phosphoramidate heteroduplex at a rate comparable to tha

148 , which involves the formation of a covalent phosphoramidate histidine-DNA adduct for cell-to-cell tr

149 oxicity and DTD activity for the 2-series of phosphoramidates; however, there was no correlation betw

150 y Ala was shown to abolish the adenylate and phosphoramidate hydrolase activity for hHint3-1.

151 pared the aminoacyl-adenylate and nucleoside phosphoramidate hydrolase activity of hHint1 and Escheri

152 mical and structural bases for the adenosine phosphoramidate hydrolase activity of rabbit Hint, we sy

153 acts of CEM cells, further suggesting that a phosphoramidate hydrolase may be responsible for intrace

154 that hHint3-1 and hHint3-2 are adenylate and phosphoramidate hydrolases with apparent second-order ra

155 ilon-(N-alpha-acetyl lysine methyl ester) 5'-phosphoramidate) hydrolases related to the rabbit histid

156 We also report here the presence of O-methyl phosphoramidate in wild-type strain 81-176 capsular poly

157 he duplexes formed by the isosequential beta-phosphoramidates in antiparallel and parallel orientatio

158 cid-catalyzed hydrolysis of the newly formed phosphoramidates incorporates one oxygen atom from H2(16

159 perties of the oligoribonucleotide N3'-->P5' phosphoramidates indicate that these compounds can be us

160 The oligo-N3'-->P5' phosphoramidate inhibited telomerase activity in cells i

161 ster intermediate or formation of a circular phosphoramidate intermediate, using an internal RNA nitr

162 nucleoside residues and phosphorothioate and phosphoramidate internucleosidic linkages were synthesiz

163 These RNA analogs contain N3'-->P5' phosphoramidate internucleotide linkages which replaced

164 hanism of action of the piperidyl nucleoside phosphoramidates involves the intracellular release of t

165 observation is that the N3'-H moiety in N3'-phosphoramidate is a flexible moiety that can change the

166 lization of the C3'-endo conformation in N3'-phosphoramidate is primarily due to aqueous solvation ra

167 Activation of the benzotriazolyl piperidyl phosphoramidates is followed by P-N bond hydrolysis; thi

168 between iridium(III) and a 1,3-N,O-chelating phosphoramidate ligand has been used to develop a protoc

169 a "Trojan horse" antibiotic that contains a phosphoramidate linkage to adenosine monophosphate at it

170 -guanylyl intermediate that is most likely a phosphoramidate linkage to His(46).

171 ptide with a modified AMP attached through a phosphoramidate linkage to the alpha-carboxyl group of t

172 n of the normal phosphodiester of DNA into a phosphoramidate linkage yields a nucleic acid that behav

173 lability and base stability, diagnostic of a phosphoramidate linkage.

174 present study, GNA analogues with N2'-->P3' phosphoramidate linkages (npGNA) have been synthesized a

175 reo-uniform cationic N-(dimethylamino-propyl)phosphoramidate linkages [e.g. d(T+T-)7T, d(T+T-)2(T+C-)

176 e 5' exon mimic with five internal N3'-->P5' phosphoramidate linkages binds 4-fold more tightly than

177 ies of oligonucleotides composed entirely of phosphoramidate linkages have been published, little is

178 phosphodiester bonds with positively-charged phosphoramidate linkages results in more efficient tripl

179 of the phosphodiester backbone with cationic phosphoramidate linkages, either N,N-diethylethylenediam

180 aminoribonucleosides connected via N3'-->P5' phosphoramidate linkages, replacing the native RNA O3'--

181 horothioate and of d(ATGAC)rU with N3'-->P5' phosphoramidate linkages.

182 ate for a self-replicating system based upon phosphoramidate linkages.

183 second, unique reaction, producing a stable phosphoramidate-linked analogue of acyl-adenylated aspar

184 hydrolyzes the naturally occurring aspartyl phosphoramidate McC7 and synthetic peptidyl sulfamoyl ad

185 dwide, produces a CPS with a unique O-methyl phosphoramidate (MeOPN) modification on specific sugar r

186 decorated nonstoichiometrically with methyl phosphoramidate (MeOPN).

187 xyls as cyclic phosphates, phosphonates, and phosphoramidates; methylation at nitrogen or hydroxyls a

188 nuclease-resistant oligonucleotide N3'-->P5' phosphoramidates might serve as RNA-like decoys and disr

189 >P5' phosphoramidates, and particularly thio-phosphoramidates, might be further developed as selectiv

190 are, and the pathway for the assembly of the phosphoramidate moiety in the CPS of C. jejuni is unknow

191 l-adenylate (AIPA) over tryptamine adenosine phosphoramidate monoester (TpAd).

192 ing alternating negatively charged N3'-->P5' phosphoramidate monoester and positively charged phospho

193 ociated with greater intracellular levels of phosphoramidate monoester and/or phosphorylated AZT.

194 wed by enzymatic hydrolysis of the resulting phosphoramidate monoester.

195 as a substrate, but not tryptamine adenosine phosphoramidate monoester.

196 is of the observed antiviral activity of AZT phosphoramidate monoesters 3a and 4a in PBMCs and CEM ce

197 y and intracellular metabolism of nucleoside phosphoramidate monoesters are distinct from that of pho

198 s and anticancer activity of a series of AZT phosphoramidate monoesters containing amino acid methyl

199 A series of phosphoramidate monoesters of 3'-azido-3'-deoxythymidine

200 The addition of a phosphoramidate motif to the gemcitabine can protect it

201 hypothesis that 3 breaks down into an active phosphoramidate mustard and a reactive vinyl sulfone.

202 The phosphoramidate NH proton signal could be observed in DM

203 synthesis of radiolabeled ammonium hydrogen phosphoramidate [(NH(4))H(32)PO(3)NH(2)] which is achiev

204 phodiester linker replaced by an N3' --> P5' phosphoramidate (NP) group have been used to establish a

205 the effect of oligonucleotide N3'-->P5' thio-phosphoramidate (NP), which targets template RNA compone

206 Using oligonucleotide N3'-->P5' phosphoramidates (NPs) we have identified a region of th

207 the discovery of a beta-d-2'-Cl,2'-F-uridine phosphoramidate nucleotide 16, as a nontoxic pan-genotyp

208 clic phosphate nucleotide, and PSI-353661, a phosphoramidate nucleotide, are prodrugs of beta-D-2'-de

209 The phenylmethoxyalaninyl phosphoramidate of abacavir was prepared in good yield i

210 illonite-catalyzed oligomerization of the 5'-phosphoramidate of adenosine are discussed.

211 Also prepared was the corresponding phosphoramidate of the guanine nucleoside analogue "carb

212 illonite-catalyzed oligomerization of the 5'-phosphoramidates of adenosine are investigated.

213 n reactions of the adenine derivatives of 5'-phosphoramidates of adenosine on montmorillonite are inv

214 purification of uniformly modified N3'-->P5' phosphoramidate oligodeoxy-nucleotides, as well as their

215 ow here that a lipid-modified N3'-->P5' thio-phosphoramidate oligonucleotide (GRN163L) inhibits telom

216 ifferences in the properties of N3'- and N5'-phosphoramidate oligonucleotide analogs.

217 Collectively, these studies suggest that phosphoramidate oligonucleotides can serve as potent and

218 and up to 99% by anti-c-myc and anti-bcr-abl phosphoramidate oligonucleotides, respectively, in a seq

219 ated systemically with equal doses of either phosphoramidate or phosphorothioate c-myc antisense or m

220 between the N3 of A2451 and the nonbridging phosphoramidate oxygen by using chemical protection and

221 A) between the A2451 N3 and the nonbridging phosphoramidate oxygen of CCdApPmn suggested that the ca

222 -specific antibodies and the lability of the phosphoramidate (P-N) bond.

223 The mode of inhibition for phosphoramidate peptidomimetic inhibitors of prostate-sp

224 rmed by the all anionic alternating N3'-->P5'phosphoramidate-phosphodiester oligothymidylate and poly

225 All the phosphoramidates prepared were L-alanine derivatives wit

226 6-diaminopurine nucleosides (DAPNs) to their phosphoramidate prodrug (PD) substantially blocks the co

227 displays a superior profile compared to its phosphoramidate prodrug analogues (e.g., 4) described pr

228 Thus, phosphoramidate prodrug derivatives of the monophosphate

229 citabine (2',2'-difluorodeoxycytidine, dFdC) phosphoramidate prodrug designed for the intracellular d

230 A novel nitroheterocyclic bis(haloethyl)phosphoramidate prodrug linked through lysine to a ptero

231 A phosphoramidate prodrug of 2'-deoxy-2'-alpha-fluoro-beta

232 for the first time the stereochemistry of a phosphoramidate prodrug with biological activity.

233 Phosphoramidate prodrugs (8-10) of phosphate-containing

234 vitro evaluation of 5-fluoro-2'-deoxyuridine phosphoramidate prodrugs 2a and 3b against L1210 mouse l

235 We have synthesized a series of gemcitabine phosphoramidate prodrugs and screened for cytostatic act

236 Phosphoramidate prodrugs are a critical component of pro

237 These phosphoramidate prodrugs contain an ester group that und

238 Chemical reduction of the phosphoramidate prodrugs led to rapid expulsion of the c

239 We found that phosphoramidate prodrugs of 2'-deoxy-2'-spirooxetane rib

240 further extended the development of the aryl phosphoramidate prodrugs of 2,3-O-isopropylidene-4-eryth

241 Phosphoramidate prodrugs of a 2'-oxetane 2-amino-6-O-met

242 Phosphoramidate prodrugs of the 5'-phosphate derivative

243 Specifically, we have developed phosphoramidate prodrugs of the anticancer nucleotide 5-

244 The most potent phosphoramidate prodrugs of these compounds have IC50 va

245 series of 2- and 3-substituted indolequinone phosphoramidate prodrugs targeted to DT-diaphorase (DTD)

246 series of 2- and 3-substituted indolequinone phosphoramidate prodrugs was synthesized, and the compou

247 gate the activation mechanisms of nucleoside phosphoramidate prodrugs.

248 us to convert adenine derivative 1 into two phosphoramidate prodrugs.

249 rted racemic mixtures of chiral bioreductive phosphoramidate prodrugs.

250 We report the application of phosphoramidate pronucleotide (ProTide) technology to th

251 rase, raising the question as to whether our phosphoramidate ProTide approach could effectively deliv

252 We report the application of the phosphoramidate ProTide approach, developed by us for an

253 We herein report the application of phosphoramidate ProTide technology to bypass the rate-li

254 We report herein the application of the phosphoramidate ProTide technology to improve the metabo

255 We report the application of our phosphoramidate ProTide technology to the ribonucleoside

256 zidoadenosine (1) and the application of the phosphoramidate ProTide technology to this nucleoside.

257 irals as it offers many of the advantages of phosphoramidate ProTides but without the chirality issue

258 These results confirm that phosphoramidate ProTides can deliver monophosphates of r

259 rent nucleosides was compared to that of the phosphoramidate ProTides.

260 Structural assignments for thymidine phosphoramidate reaction products were made by analogy t

261 8) was also carried out in the hope that the phosphoramidates released might be phosphatase-resistant

262 Stability studies revealed that > 99% of the phosphoramidates remained intact after incubation for >

263 potent than the unsubstituted bis(haloethyl)phosphoramidate, respectively.

264 series of fluorogenic tryptamine nucleoside phosphoramidates revealed that hHint3-1 and hHint3-2 are

265 on of aminohexanoic acid (AH) linkers in the phosphoramidate scaffold improved their PSMA binding and

266 otently than its parental nonconjugated thio-phosphoramidate sequence (GRN163).

267 Phosphoramidate serves as a useful phosphodonor reagent

268 ay structure was determined establishing the phosphoramidate stereochemistry as Sp, thus correlating

269 Comparison of phosphodiester and phosphoramidate structures suggests that their backbones

270 Ca(II)-stimulated PvuII binding for a phosphoramidate-substituted oligonucleotide is comparabl

271 Oligonucleotide duplexes containing a phosphoramidate substitution at the scissile phosphates

272 onformational perturbation caused by the N5'-phosphoramidate substitution is identified and suggested

273 little is known about how singly substituted phosphoramidate substitutions affect the thermodynamics

274 drolysis of adenylylated and/or guanylylated phosphoramidate substrates by hinT.

275 racterized with respect to purine nucleoside phosphoramidate substrates.

276 er, that DNA analogs with modified N3'-->P5' phosphoramidate sugar-phosphate backbones are stable and

277 s of the oligo-2'-fluoronucleotide N3'-->P5' phosphoramidates suggest that they may have good potenti

278 Results with a phosphoramidate tetramer and thiophosphoramidate hexamer

279 ly all the CheY variants reacted faster with phosphoramidate than acetyl phosphate.

280 10-400-fold less cytotoxic in vitro than the phosphoramidate that lacks the lysine-pteroyl moiety.

281 fied peptides release the positively charged phosphoramidate that via gas-phase intramolecular elimin

282 The ability of zwitterionic phosphoramidates to form complexes with complementary DN

283 ility of the alpha-oligonucleotide N3'-->P5' phosphoramidates to form duplexes was studied using ther

284 r the installation of phosphorus-stereogenic phosphoramidates to nucleosides through a dynamic stereo

285 day for 6 consecutive days), survival of the phosphoramidate-treated mice was significantly longer th

286 oceeds with a wide range of phosphonates and phosphoramidates under mild conditions and gives straigh

287 ized and used to prepare the oligonucleotide phosphoramidates using a solid phase methodology based o

288 phosphoserine peptides to the corresponding phosphoramidates, using 2-aminobenzylamine.

289 isosequential oligonucleotide N3'-->P5' thio-phosphoramidate was able to inhibit telomerase activity

290 osition of the abacavir phenylethoxyalaninyl phosphoramidate was evaluated in Cynomolgus monkeys.

291 n HME50-5E cells by the oligonucleotide thio-phosphoramidates was also sequence specific.

292 AZT-MP and substantial amounts of either phosphoramidate were detected in PBMCs and CEM cells tre

293 Twenty-two phosphoramidates were prepared, including variations in

294 veral mixed base 9-13mer oligoribonucleotide phosphoramidates were synthesized with step-wise couplin

295 eactivity between N-aliphatic and N-aromatic phosphoramidates were verified by electrochemistry.

296 alogous results were observed for anti-c-myc phosphoramidates, where a complete cytostatic effect for

297 groups on phosphopeptides, are converted to phosphoramidates with carbodiimide assistance.

298 as converted to a series of 06 arylaminoacyl phosphoramidates with ester and amino acid variation.

299 ng peptides and their subsequent reaction to phosphoramidates with phosphite esters before they are c

300 stimulated up to 8-fold by the phosphodonor phosphoramidate, with stimulation again dependent on Asp